Hélène Regnault
Research Subjects
Hélène Regnault has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
Giuliana Amaddeo
Department of Hepatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor-Albert Chenevier University Hospital, Créteil, France
6 shared publications- Giuliana Amaddeo
Service d'Hépatologie, AP-HP Henri Mondor, Créteil, France
6 shared publications Marie Lequoy
INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France; Service d'Hépatologie, AP-HP Saint-Antoine, France
6 shared publications- Clémence Hollande
AP-HP, Liver Cancer and Innovative Therapy Unit, Hôpital Beaujon, 100 Boulevard du Général Leclerc, 92110, Clichy, France
5 shared publications Manon Allaire
Hepatogastroenterology Department, La Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France; INSERM UMR 1138, Centre de recherche des Cordeliers, « Genomic instability, metabolism, immunity and liver tumorigenesis », 75006 Paris, France
5 shared publications- Nathalie Ganne-Carrié
Hepatology Department, AP-HP, Hospital Avicenne, Avicenne, France
5 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (9) , 101915
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma
- 12 June 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (9) , 101915
Open AccessClinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma
- 27 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF13
Long-term Survival and Cure Fraction in Patients with Advanced Hepatocellular Carcinoma under Immunotherapy in Randomized Controlled Trials and Real-world Data
Purpose: Immune checkpoint inhibitors (ICI) can induce long-term survival and even cancer cure in several cancers. Mixture cure models (MCM) estimate the fraction of long-term survivors and cured patients but have not been applied in hepatocellular carcinoma (HCC). Experimental Design: We identified phase III randomized trials of first-line ICI in advanced HCC with mature follow-up (≥30 months) and analyzed a cohort of patients with HCC treated with atezolizumab–bevacizumab. After reconstructing Kaplan–Meier curves, MCMs estimated the long-term survivors’ fraction [overall survival (OS)] and cure fractions [progression-free survival (PFS)]. Results: In HIMALAYA (median follow-up of 60 months), long-term survival was 12.8% [95% confidence interval (CI), 8.5%–18.6%] with durvalumab–tremelimumab versus 5.2% (95% CI, 2.6%–10.2%) with sorafenib; the cure fraction was not assessable. In CheckMate 9DW (median follow-up: 35.2 months), long-term survival was 8.7% (95% CI, 0.2%–81.3%) versus 4.1% (95% CI, 0.1%–66.1%), and cure fractions were 17.8% (95% CI, 12%–25.8%) versus 3.5% (95% CI, 0.7%–16.7%) for nivolumab–ipilimumab and sorafenib/lenvatinib, respectively, with long-term OS estimates remaining exploratory due to limited late numbers at risk. In RATIONALE-301, long-term survival was 25.2% (95% CI, 19.2–32.2) with tislelizumab versus 15.4% (95% CI, 10–22.8) with sorafenib. The IMbrave150 trial was not analyzed due to insufficient follow-up (15.6 months). Among a clinical cohort of 1,581 patients treated with atezolizumab–bevacizumab (median follow-up: 34.7 months), long-term survival was 12.3% (95% CI, 9.3%–16.1%), and the cure fraction was 7.9% (95% CI, 6.3%–9.8%). In 1,187 patients meeting IMbrave150 criteria, long-term survival reached 15.4% (95% CI, 10.6%–18.5%), and the cure fraction was 9.1% (95% CI, 7.3%–11.4%). Albumin–bilirubin score and hepatitis C predicted long-term survival, and albumin and hepatitis C predicted cure. Conclusions: Across trials and real-world data, ICI combinations achieve long-term survival in 10% to 15% of patients with advanced HCC, with cure fractions of 7% to 9%.
- 27 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF13
Long-term Survival and Cure Fraction in Patients with Advanced Hepatocellular Carcinoma under Immunotherapy in Randomized Controlled Trials and Real-world Data
Purpose: Immune checkpoint inhibitors (ICI) can induce long-term survival and even cancer cure in several cancers. Mixture cure models (MCM) estimate the fraction of long-term survivors and cured patients but have not been applied in hepatocellular carcinoma (HCC). Experimental Design: We identified phase III randomized trials of first-line ICI in advanced HCC with mature follow-up (≥30 months) and analyzed a cohort of patients with HCC treated with atezolizumab–bevacizumab. After reconstructing Kaplan–Meier curves, MCMs estimated the long-term survivors’ fraction [overall survival (OS)] and cure fractions [progression-free survival (PFS)]. Results: In HIMALAYA (median follow-up of 60 months), long-term survival was 12.8% [95% confidence interval (CI), 8.5%–18.6%] with durvalumab–tremelimumab versus 5.2% (95% CI, 2.6%–10.2%) with sorafenib; the cure fraction was not assessable. In CheckMate 9DW (median follow-up: 35.2 months), long-term survival was 8.7% (95% CI, 0.2%–81.3%) versus 4.1% (95% CI, 0.1%–66.1%), and cure fractions were 17.8% (95% CI, 12%–25.8%) versus 3.5% (95% CI, 0.7%–16.7%) for nivolumab–ipilimumab and sorafenib/lenvatinib, respectively, with long-term OS estimates remaining exploratory due to limited late numbers at risk. In RATIONALE-301, long-term survival was 25.2% (95% CI, 19.2–32.2) with tislelizumab versus 15.4% (95% CI, 10–22.8) with sorafenib. The IMbrave150 trial was not analyzed due to insufficient follow-up (15.6 months). Among a clinical cohort of 1,581 patients treated with atezolizumab–bevacizumab (median follow-up: 34.7 months), long-term survival was 12.3% (95% CI, 9.3%–16.1%), and the cure fraction was 7.9% (95% CI, 6.3%–9.8%). In 1,187 patients meeting IMbrave150 criteria, long-term survival reached 15.4% (95% CI, 10.6%–18.5%), and the cure fraction was 9.1% (95% CI, 7.3%–11.4%). Albumin–bilirubin score and hepatitis C predicted long-term survival, and albumin and hepatitis C predicted cure. Conclusions: Across trials and real-world data, ICI combinations achieve long-term survival in 10% to 15% of patients with advanced HCC, with cure fractions of 7% to 9%.
- Open Access
- 30 March 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 239, 116704
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
- 30 March 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 239, 116704
Open AccessClinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
- Open Access
- 17 March 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (6) , 101827
Atezolizumab–bevacizumab in very elderly with hepatocellular carcinoma: Age alone is not a limiting factor except in ALBI grade 3
- 17 March 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (6) , 101827
Open AccessAtezolizumab–bevacizumab in very elderly with hepatocellular carcinoma: Age alone is not a limiting factor except in ALBI grade 3
- Open Access
- 1 December 2024
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 13 (6) , 974-990
Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review
Review Article Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review Paul Vigneron, Maria Stella Franzè, Julia Chalaye, Vania Tacher, Anna Sessa, Alain Luciani, Hicham Kobeiter, Hélène Regnault, Ancuta Bejan, Julien Calderaro, Rami Rhaiem, Daniele Sommacale, Giovanni Raimondo, Vincent Leroy, Raffaele Brustia, Giuliana Amaddeo
- 1 December 2024
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 13 (6) , 974-990
Open AccessSelective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review
Review Article Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review Paul Vigneron, Maria Stella Franzè, Julia Chalaye, Vania Tacher, Anna Sessa, Alain Luciani, Hicham Kobeiter, Hélène Regnault, Ancuta Bejan, Julien Calderaro, Rami Rhaiem, Daniele Sommacale, Giovanni Raimondo, Vincent Leroy, Raffaele Brustia, Giuliana Amaddeo
- Open Access
- 23 August 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (11) , 101192
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study
- 23 August 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (11) , 101192
Open AccessPatient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study
- Open Access
- 23 August 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (1) , 101539
Prognostic factors influencing outcomes in hepatocellular carcinoma patients undergoing selective internal radiation therapy
- 23 August 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (1) , 101539
Open AccessPrognostic factors influencing outcomes in hepatocellular carcinoma patients undergoing selective internal radiation therapy
- Open Access
- 29 June 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (10) , 101160
MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
- 29 June 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (10) , 101160
Open AccessMASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
- Open Access
- 17 July 2023
- Published by Elsevier in Annals of Hepatology
- Vol. 28 (6) , 101141
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?
- 17 July 2023
- Published by Elsevier in Annals of Hepatology
- Vol. 28 (6) , 101141
Open AccessImpact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?
- Open Access
- 29 January 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (4) , 100689
TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
- 29 January 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (4) , 100689
Open AccessTACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial